Bayer HealthCare Pharmaceuticals Asia Pacific sales rose 13.1% in 2014 and reached nearly €3.3 billion with Vietnam a standout performer with a gain of 31%, executives in the region said on April 1 at a press conference in Singapore, adding that the growth has also set the stage for stepped-up clinical trials in the region.
Wei Jiang, regional head, and Dr. Chuan Kit Foo, head of Global Medical Affairs Asia, at Bayer HealthCare Pharmaceuticals Asia Pacific, noted at the press conference that the company's overall pipeline has 57 development compounds in Phase I to III of clinical development; with about a third in oncology and also a third in cardiology.
"In 2015, three new Phase III oncology studies and three Phase III cardiology studies in two indications will begin in eight countries across Asia Pacific," Foo said in a press release.
The number of ongoing clinical trials that Bayer has conducted since 2007 has increased threefold, with 66 in Asia Pacific and 20 in Singapore alone, Foo said. This includes joint cancer research collaborations which have led to the setup of an Integrated Translational Oncology Network in 2013, he said.
- here's the Bayer HealthCare Asia Pacific release